Combinations and Interfaces

CBD recognizes enormous opportunities at the interface of these cargo classifications. For example, combination of small molecule encapsulation with antibodies provide opportunities in developing innovative and impactful alternates to antibody-drug conjugates (ADCs) (Bioconjugate Chem. 2015, 26, 2198–2215). Similarly, combining the delivery of proteins and nucleic acids present opportunities in novel cell-based therapies, including in genome editing strategies such TALEN and CRISPR. CBD investigators are collaboratively targeting these opportunities at the interface of different technology platforms and cargoes.